TNDM analyst estimates
Tandem Diabetes (TNDM) analyst ratings, the average price target and its range, and every firm's latest call.
TNDM analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 13, 2026 | Mizuho Securities | Tandem Diabetes price target lowered to $18 from $20 at Mizuho | $18.00 |
| Oct 6, 2026 | Barclays | Tandem Diabetes initiated with an Equal Weight at Barclays | $18.00 |
| Aug 7, 2026 | Canaccord Genuity | Tandem Diabetes price target raised to $40 from $35 at Canaccord | $40.00 |
| Aug 7, 2026 | RBC Capital | Tandem Diabetes price target lowered to $26 from $30 at RBC Capital | $26.00 |
| Jul 28, 2026 | UBS | Tandem Diabetes resumed with a Neutral at UBS | $18.00 |
| Jun 23, 2026 | Deutsche Bank | Tandem Diabetes initiated with a Hold at Deutsche Bank | $15.50 |
| Jun 1, 2026 | Wells Fargo | Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo | $27.00 |
| May 27, 2026 | Goldman Sachs | Tandem Diabetes price target lowered to $21 from $24 at Goldman Sachs | $21.00 |
| May 11, 2026 | Barclays | Tandem Diabetes price target lowered to $55 from $56 at Barclays | $55.00 |
| May 8, 2026 | Mizuho Securities | Tandem Diabetes price target raised to $24 from $22 at Mizuho | $24.00 |
| Apr 24, 2026 | Redburn Partners | Tandem Diabetes price target raised to $45 from $36 at Rothschild & Co Redburn | $45.00 |
| Feb 23, 2026 | Barclays | Tandem Diabetes price target raised to $56 from $55 at Barclays | $56.00 |
| Feb 23, 2026 | Goldman Sachs | Tandem Diabetes price target raised to $28 from $25 at Goldman Sachs | $28.00 |
| Feb 23, 2026 | Lake Street | Tandem Diabetes upgraded to Buy from Hold at Lake Street | $50.00 |
| Feb 23, 2026 | Truist Financial | Tandem Diabetes price target raised to $27 from $24 at Truist | $27.00 |
- 20 firms rate TNDM: 9 buy, 11 hold, 0 sell.
- The average price target is $22.94 from 8 analysts, from $15.50 to $40.00.
Updated 2026-11-02 23:12 UTC